Get the Stockscreener App
0.1305
7.38%
-0.0104
After Hours:
.13
-0.0005
-0.38%
Cns Pharmaceuticals Inc stock is traded at $0.1305, with a volume of 1.34M.
It is down -7.38% in the last 24 hours and down -16.98% over the past month.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.
See More
Previous Close:
$0.1409
Open:
$0.1409
24h Volume:
1.34M
Relative Volume:
0.26
Market Cap:
$4.20M
Revenue:
-
Net Income/Loss:
$-18.61M
P/E Ratio:
-0.013
EPS:
-10.05
Net Cash Flow:
$-13.91M
1W Performance:
-6.79%
1M Performance:
-16.98%
6M Performance:
-99.28%
1Y Performance:
-99.77%
1-Day Range:
$0.13
$0.1418
1-Week Range:
$0.13
$0.1464
52-Week Range:
$0.0955
$137.50
Cns Pharmaceuticals Inc Stock (CNSP) Company Profile
Name
Cns Pharmaceuticals Inc
Sector
Industry
Phone
1-800-946-9185
Address
2100 WEST LOOP SOUTH, HOUSTON
Cns Pharmaceuticals Inc Stock (CNSP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-28-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Aug-24-20 | Initiated | Ladenburg Thalmann | Buy |
Cns Pharmaceuticals Inc Stock (CNSP) Latest News
Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference - Marketscreener.com
Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference - StockTitan
Cns Pharmaceuticals Inc (CNSP)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
Examining Cns Pharmaceuticals Inc (CNSP) stock is warranted - US Post News
CNS Therapeutics Market 2024 Share, Growth Forecast and Industry Outlook 2032 | Eli Lilly and Co. - 대구포스트
CNS Pharma (NASDAQ:CNSP) Stock Quotes, Forecast and News Summary - Benzinga
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation at the 24th Annual Biotech in Europe Forum - MSN
A new trading data show Cns Pharmaceuticals Inc (CNSP) is showing positive returns. - SETE News
Do investors need to be concerned about Cns Pharmaceuticals Inc (CNSP)? - US Post News
CNS (Central Nervous System) Therapeutics Market 2024 Size, Status and Global Outlook 2031 - Newstrail
CNS Pharmaceuticals to Present at the 24th Annual Biotech in Europe Forum - AccessWire
CNS Pharmaceuticals to Present at the 24th Annual Biotech in Europe Forum - StockTitan
Ratio Review: Analyzing Cns Pharmaceuticals Inc (CNSP)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Cns Pharmaceuticals Inc (CNSP) Stock: 52-Week Performance Insights and Trading Volume - The InvestChronicle
An analyst sees good growth prospects for Cns Pharmaceuticals Inc (CNSP) - SETE News
What was Cns Pharmaceuticals Inc (CNSP)’s performance in the last session? - US Post News
Stock Performance Spotlight: Cns Pharmaceuticals Inc (CNSP) Ends the Day at 0.15, Down by -0.54 - The Dwinnex
CNS Pharmaceuticals regains NASDAQ compliance - Investing.com
CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement - AccessWire
CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement - StockTitan
Such Is The Power Of Cns Pharmaceuticals Inc (NASDAQ: CNSP) - Stocks Register
CNS Pharmaceuticals (NASDAQ:CNSP) Upgraded to “Buy” at Maxim Group - Defense World
CNSP Stock: Exploring Cns Pharmaceuticals Inc’s Growth - The InvestChronicle
Maxim raises CNS Pharmaceuticals to buy, cites improved financial position - Investing.com
Is Cns Pharmaceuticals Inc (CNSP) a good investment opportunity? - US Post News
Gaining Ground: Cns Pharmaceuticals Inc (CNSP) Closes Lower at 0.14, Down -4.53 - The Dwinnex
TSX 60 Index (TXSX) QuotePress Release - The Globe and Mail
TSX Utilities Capped Index (TTUT) QuotePress Release - The Globe and Mail
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
Cns Pharmaceuticals Inc (CNSP) expanding its growth trajectory ahead - SETE News
Cns Pharmaceuticals Inc (CNSP-Q) QuotePress Release - The Globe and Mail
CNS Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference - AccessWire
CNS Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Yahoo Finance
Examining Cns Pharmaceuticals Inc (CNSP) more closely is necessary - US Post News
Cns Pharmaceuticals Inc (CNSP)’s Day in Review: Closing at 0.16, Up by 6.94 - The Dwinnex
CNSP’s Stock Market Labyrinth: Navigating 2023’s Gains and Declines - The InvestChronicle
IBN Announces Latest Episode of The BioMedWire Podcast featuring John Climaco, CEO of CNS Pharmaceuticals Inc. - GlobeNewswire
IBN Announces Latest Episode of The BioMedWire Podcast featuring John Climaco, CEO of CNS Pharmaceuticals Inc. - Yahoo Finance
Market Resilience: Cns Pharmaceuticals Inc (CNSP) Finishes Weak at 0.17, Down -7.11 - The Dwinnex
CNS Pharmaceuticals to Participate in at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar - AccessWire
CNS Pharmaceuticals to Participate in at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar - Yahoo Finance
Stocks of Cns Pharmaceuticals Inc (CNSP) are poised to climb above their peers - SETE News
CNSP’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
CNS Pharmaceuticals to Participate in Virtual Investor CEO Connect Segment - AccessWire
CNS Pharmaceuticals to Participate in Virtual Investor CEO Connect Segment - StockTitan
CNS Pharmaceuticals to Present at the Virtual Investor GBM Spotlight Event - Quantisnow
Cns Pharmaceuticals Inc Inc. (CNSP) Price Performance: A Technical Analysis Perspective - The InvestChronicle
Financial Health Report: Cns Pharmaceuticals Inc (CNSP)’s Ratios Tell a Tale - The Dwinnex
CNSP (CNS Pharmaceuticals) EV-to-EBIT : -0.16 (As of Aug. 17, 2024) - GuruFocus.com
CNS Pharmaceuticals Reports Second Quarter 2024 Financial Results - AccessWire
CNS Pharmaceuticals Reports Second Quarter 2024 Financial Results - StockTitan
Cns Pharmaceuticals Inc Stock (CNSP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):